Keros Therapeutics (NASDAQ:KROS) Downgraded to Neutral Rating by Guggenheim

Guggenheim downgraded shares of Keros Therapeutics (NASDAQ:KROS - Free Report) from a buy rating to a neutral rating in a report published on Monday morning, MarketBeat reports.

A number of other equities analysts have also weighed in on KROS. BTIG Research lowered shares of Keros Therapeutics from a "buy" rating to a "neutral" rating in a research report on Thursday. Wells Fargo & Company upped their target price on shares of Keros Therapeutics from $88.00 to $111.00 and gave the stock an "overweight" rating in a research report on Wednesday, December 11th. William Blair lowered shares of Keros Therapeutics from an "outperform" rating to a "market perform" rating in a research report on Thursday. TD Cowen lowered shares of Keros Therapeutics from a "buy" rating to a "hold" rating in a research report on Thursday. Finally, HC Wainwright decreased their price target on shares of Keros Therapeutics from $100.00 to $47.00 and set a "buy" rating on the stock in a research note on Friday. Four research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Keros Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $81.33.

Keros Therapeutics Stock Performance

Shares of KROS traded up $0.59 during mid-day trading on Monday, reaching $19.42. The stock had a trading volume of 2,194,875 shares, compared to its average volume of 464,391. The firm has a market cap of $786.65 million, a price-to-earnings ratio of -3.61 and a beta of 1.20. Keros Therapeutics has a 12 month low of $15.67 and a 12 month high of $73.00. The business has a fifty day moving average of $59.11 and a 200 day moving average of $52.69.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last issued its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing analysts' consensus estimates of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The company had revenue of $0.39 million for the quarter. During the same period last year, the company posted ($1.33) EPS. The business's revenue was up 4750.0% compared to the same quarter last year. On average, research analysts forecast that Keros Therapeutics will post -5.26 EPS for the current fiscal year.

Institutional Trading of Keros Therapeutics

A number of institutional investors have recently modified their holdings of the company. Charles Schwab Investment Management Inc. boosted its stake in Keros Therapeutics by 14.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 260,120 shares of the company's stock worth $15,105,000 after purchasing an additional 32,492 shares in the last quarter. Assenagon Asset Management S.A. acquired a new stake in Keros Therapeutics in the 2nd quarter worth approximately $1,118,000. Intech Investment Management LLC acquired a new stake in Keros Therapeutics in the 3rd quarter worth approximately $603,000. Bank of New York Mellon Corp boosted its stake in Keros Therapeutics by 18.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 118,388 shares of the company's stock worth $5,410,000 after purchasing an additional 18,755 shares in the last quarter. Finally, Point72 Asset Management L.P. boosted its stake in Keros Therapeutics by 155.9% in the 3rd quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company's stock worth $55,025,000 after purchasing an additional 577,220 shares in the last quarter. 71.56% of the stock is currently owned by institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.